Nuwellis Investor Presentation Deck
March 2023, 26 slides
  1. Nuwellis
  2. Related Decks
  3. Investor Presentation Decks
investor presentation | Nuwellis
safe harbor statement | Nuwellis
our mission is dedicated to transforming the lives of patients suffering from fluid overload through science collaboration and innovation mun | Nuwellis
investment highlights | Nuwellis
executive leadership team i | Nuwellis
fluid overload is associated with greater mortality fluid overload is the leading cause of death for critically ill patients in the within days excess fluid following cardiac surgery leads to three fold increase in mortality at days of heart failure hospitalizations are due to signs and symptoms of fluid overload toons days days | Nuwellis
diuretics significant limitations as current standard of care high risk of long term use of diuretics is associated with kidney damage diuretics provide insufficient symptom relief and are associated with worsening heart failure and increased mortality after discharge of heart failure patients have poor diuretic response damage discharge response | Nuwellis
clinically superior solution for fluid overload | Nuwellis
multiple growth opportunities moving to standard of care in fluid overload tam treating the most vulnerable | Nuwellis
expanding use of ultrafiltration across hospital specialty units improves outcomes for fluid overloaded patients cardiac surgery liver transplants sepsis adult | Nuwellis
diuretic limitations create significant burden to hospitals systems background | Nuwellis
ultrafiltration a safe and more effective therapy than diuretics versus intravenous diuretics and hospitalizations for heart failure avoid trial adjustable ultrafiltration won more times than adjustable loop diuretics resulting in win ratios that all favored ultrafiltration over diuretics in reducing mortality and events in congested patients of venue | Nuwellis
ultrafiltration positive roi clinical and economic benefits year real world experience with ultrafiltration hospital hospital readmissions | Nuwellis
outpatient potential savings for a hospital account | Nuwellis
driving use of ultrafiltration in the outpatient setting prevents hospitalization and lowers readmission rates near term opportunity heart failure mid term opportunity advanced liver disease | Nuwellis
making the standard of care in fluid overload | Nuwellis
driving penetration and increased utilization across territories or | Nuwellis
growing pediatric business | Nuwellis
market driven demand to improve pediatric therapy | Nuwellis
the solution introducing | Nuwellis
novel technology with strong portfolio | Nuwellis
key near term milestones | Nuwellis
financial snapshot annual revenue | Nuwellis
investment highlights | Nuwellis
dedicated to transforming the lives of patients suffering from fluid overload through science collaboration and innovation | Nuwellis
market size sources | Nuwellis
See More
Nuwellis
Investor Presentation Decks
Medical Devices Decks
Healthcare Decks
Explore Topics
Hospital
Liver
Recent decks by Nuwellis
Investor Presentation
August 2023
See all presentations by Nuwellis (2 decks)
Related decks
Genetron
IPO
July 2020
NeuroBo Pharmaceuticals
Investor Presentation
January 2024
MindMed
Investor Presentation
April 2021
Arbutus Biopharma
Results
November 2022
NeuroBo Pharmaceuticals
Investor Presentation
December 2023
DocGo
SPAC
May 2021
AstraZeneca
Investor Event
December 2022
Centessa
IPO
May 2021
Recent decks by Nuwellis
See all presentations (2 decks)
Investor Presentation
August 2023
Genetron
IPO
July 2020
NeuroBo Pharmaceuticals
Investor Presentation
January 2024
MindMed
Investor Presentation
April 2021
Arbutus Biopharma
Results
November 2022
NeuroBo Pharmaceuticals
Investor Presentation
December 2023
DocGo
SPAC
May 2021
AstraZeneca
Investor Event
December 2022
Centessa
IPO
May 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights